Important Safety Information: XANAX XR is contraindicated in patients with known sensitivity to this drug or other benzodiazepines,
in patients with acute narrow-angle glaucoma, and in patients taking potent CYP3A inhibitors, such as
ketoconazole and itraconazole.
Certain adverse clinical events are a direct consequence of physical dependence
to alprazolam. These include a spectrum of discontinuation symptoms, the most
important being the possibility of seizure.
The most commonly observed adverse events in patients treated with XANAX XR in controlled
clinical trials (≥5% and at least twice the incidence observed for placebo) were: sedation (45.2% vs 22.6%),
somnolence (23.0% vs 6.0%), memory impairment (15.4% vs 6.9%), dysarthria (10.9% vs 2.6%), abnormal
coordination (9.4% vs 0.9%), ataxia (7.2% vs 3.2%), and decreased libido (6.0% vs 2.3%).
Please see full prescribing information for more information.
